EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

Tanja Mueller iD, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N Sneden, David Martin, Amanj Kurdi iD, Catherine S Thomson, Julie Clarke, Marion Bennie

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70700 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Tanja Mueller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scottish Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland.

Methods

The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024. The National Systemic Anti‐Cancer Therapy (SACT) dataset was used to identify patients and obtain details on ICI treatments and patient characteristics. Additional data sources providing information on comorbidities were linked deterministically via a unique patient identifier. All analyses were descriptive.

Results

In total, 10 394 patients in Scotland initiated their first ICI treatment between 2018 and 2024; the number of patients initiating ICIs increased substantially year‐on‐year, from 764 patients in 2018 to 2233 patients in 2024. The most commonly prescribed ICI was pembrolizumab (56.8%, n = 5908), followed by nivolumab (16.4%, n = 1700) and atezolizumab (11.3%, n = 1170); treatment was most commonly initiated for lung and chest cancers (44.1%, n = 4585), skin cancer (18.8%, n = 1955) and urological cancers (14.8%, n = 1539). While the majority of patients (66.6%, n = 6923) initiated ICI monotherapy, combination therapies—most commonly ICI with chemotherapy (18.4%, n = 1910)—were also used. Overall, 6.6% of patients ( n = 681) were on treatment for more than 2 years.

Conclusions

With the continuous addition of new ICIs, alongside the ever‐expanding list of approved indications for their use, the observed increase in ICI use is expected to continue. This increasing use of ICIs may pose challenges to health services—for instance, an increase in immune‐related adverse effects—with potential implications for clinical practice and future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedRetrospective StudiesScotlandAdolescentYoung Adult

Stichwörter der Autor:innen

Scotlandcancerimmune checkpoint inhibitorssystemic anti‐cancer therapytreatment uptake

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumab

Autor:innen und Institutionen

  • Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Public Health Scotland, Glasgow/Edinburgh, UK.
  • NHS Greater Glasgow and Clyde, Glasgow, UK.

ORCID-Profile: Tanja Mueller, Amanj Kurdi

Förderung

  • Scottish Government

Zitieren

APA

Mueller, T., Crearie, C., Lu, L., Pan, J., Sneden, F. N., Martin, D., Kurdi, A., Thomson, C. S., Clarke, J., & Bennie, M. (2026). Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70700

Vancouver

Mueller T, Crearie C, Lu L, Pan J, Sneden FN, Martin D, et al. Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70700

BibTeX
@article{Mueller2026,
  author = {Mueller, Tanja and Crearie, Christine and Lu, Liya and Pan, Jiafeng and Sneden, Fraser N and Martin, David and Kurdi, Amanj and Thomson, Catherine S and Clarke, Julie and Bennie, Marion},
  title = {Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70700}
}
Kostenlos starten →